<DOC>
	<DOCNO>NCT02338531</DOCNO>
	<brief_summary>This phase II open label Biomarker Research Study PF-03084014 non-metastatic triple-negative breast cancer patient residual disease ( cHEmoresistant ) completion standard neoadjuvant chemotherapy .</brief_summary>
	<brief_title>Biomarker Research Study PF-03084014 cHEmoresistant Triple-negative Breast cAncer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<criteria>1 . Age ≥18 year old . 2 . Female . 3 . Histological diagnosis triplenegative breast cancer ( TNBC ) breast adenocarcinoma ( ER &lt; 1 % , PR &lt; 1 % ( IHC ) HER2 01+ IHC IHC 2+ FISH CISH negative per update ASCO guideline ) . 4 . No clinical radiologic evidence distant metastasis . 5 . Presence residual primary disease least 1.5 cm U/S MRI within 14 day precede last cycle standard anthracycline taxanebased neoadjuvant chemotherapy . Patients synchronous synchronous bilateral cancer unilateral multifocal multicentric bilateral disease breast cancer allow provide histologic diagnosis TNBC find performed biopsy . 6 . Completion standard anthracycline taxanebased neoadjuvant chemotherapy . The use platinum agent combination standard neoadjuvant chemotherapy allow . 7 . ECOG Performance Status ( PS ) 0 1 8 . Adequate Bone Marrow Function : Absolute Neutrophil Count ( ANC ) ≥ 1500/μL ≥1.5 x 109/L ; Platelets ≥100000/μL ≥100 x 109/L ; Hemoglobin ≥ 9 g/dL . 9 . Adequate Renal Function : Serum creatinine ≤ 1.5 x upper limit normal ( ULN ) estimate creatinine clearance ≥ 60 ml/min . 10 . Adequate Liver Function : Total serum bilirubin ≤ 1.0 x ULN ≤ 2 x ULN case know Gilberts syndrome ; Aspartate Alanine Aminotransferase ( AST ALT ) ≤ 1.5 x ULN ; Alkaline phosphatase ≤ 2.5 x ULN . 11 . For patient childbearing potential : negative serum/urine pregnancy test use accept form nonhormonal contraception study period 6 month treatment completion . 1 . Concurrent anticancer therapy current breast cancer ( hormone therapy , chemotherapy , radiotherapy , immunotherapy ) . Patients already include another therapeutic trial involve experimental drug . 2 . Pregnant lactating woman . 3 . Any prior history invasive breast cancer . 4 . Any previous history nonbreast malignancy ( except basal cell carcinoma squamous cell carcinoma skin ) precede 5 year . 5 . Known hypersensitivity study drug excipients . 6 . Patients concurrent severe and/or uncontrolled medical disease infection could compromise participation study . 7 . Subjects unable swallow oral medication .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>